Company: AMWL
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057290
Chunk: 37

Company: American Well Corp
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 37
---
 Israel Institute of Technology.

<div align='center'>20</div>

COMPENSATION DISCUSSION AND ANALYSIS This Compensation Discussion and Analysis (“CD&A”) discusses the principles and objectives underlying our policies and decisions with respect to the compensation of our named executive officers (“NEOs”), as well as other material factors relevant to an analysis of these policies and decisions regarding our 2024 executive compensation program. This CD&A is intended to be read in conjunction with the tables that immediately follow this section, which provide further compensation information for the following NEOs:

| Name                        |     | Position                                                                      |
| Ido Schoenberg, MD          |     | Chairman, Chief Executive Officer (CEO)                                       |
| Roy Schoenberg, MD, MPH (1) |     | Executive Vice Chairman, Former co-Chief Executive Officer                    |
| Phyllis Gotlib              |     | President, International                                                      |
| Mark Hirschhorn (2)         |     | Executive Vice President, Chief Financial Officer and Chief Operating Officer |
| Kurt Knight (3)             |     | Former Chief Operating Officer                                                |
| Robert Shepardson (4)       |     | Former Chief Financial Officer                                                |
| Kathy Weiler (5)            |     | Former Executive Vice President, Chief Commercial and Growth Officer          |

(1) Dr. Roy Schoenberg resigned from his role as President and co-CEO and transitioned to the role of Executive Vice Chairman of Amwell’s Board of Directors effective June 13, 2024. (2) Mr. Hirschhorn was appointed as Executive Vice President, Chief Financial Officer effective October 21, 2024, and then to his current position as Executive Vice President, Chief Financial Officer and Chief Operating Officer effective December 17, 2024. (3) Mr. Knight’s employment with the Company ended effective December 31, 2024. (4) Mr. Shepardson resigned from employment effective October 18, 2024. (5) Ms. Weiler’s employment with the Company ended effective December 31, 2024. See “Compensation Program Components – Leadership Transitions Effective in 2024” for further information regarding our 2024 leadership transitions. The primary objectives of our executive compensation program are to retain key executives, attract new talent and link compensation to achievement of business objectives. We believe our 2024 NEO compensation demonstrates the Company’s commitment to aligning executive pay with corporate performance. This CD&A provides an overview of our executive compensation philosophy, the overall objectives of